It is expected that, in order to cure the MPN disease, JAK2 inhibitors should be combined with other drugs to target simultaneously different pathways and to target the initiator hematopoietic LSK positive cell population in MPN. The gene discussed is JAK2; the disease is myeloproliferative neoplasm.